| New carotid plaque formation during follow-up | |
---|---|---|
Parameters | Yes | No |
Patient demographics | Â | Â |
   Total number of patients | 19 | 45 |
   Age at follow-up end (years)b | 70.6 ± 6.9 | 59.2 ± 12.1 |
   Sex, n (%) | 14 women (73.7) 5 men (26.3) | 39 women (86.7) 6 men (13.3) |
   Months of follow-up (months) | 40.6 ± 3.0 | 40.9 ± 3.0 |
RA-related parameters | Â | Â |
   Duration of disease at follow-up end (years) | 9.4 ± 3.9 | 11.9 ± 6.9 |
   Functional class of disease, n (%) |  |  |
Class I | 12 (63.2) | 18 (40.0) |
Class II | 6 (31.6) | 17 (37.8) |
Class III | 1 (5.3) | 9 (20.0) |
Class IV | 0 (0) | 1 (2.2) |
   Stage of disease, n (%) |  |  |
Early | 6 (31.6) | 11 (24.4) |
Moderate | 12 (63.2) | 19 (42.2) |
Severe | 1 (5.3) | 14 (31.1) |
Terminal | 0 (0) | 1 (2.2) |
   RF-positive, n (%) | 13 (68.4) | 29 (64.4) |
   hs-CRP AUC during follow-up (mg/dl × months) | 16.6 (12.4, 57.5) | 23.8 (12.3, 45.2) |
   ESR AUC during follow-up (mm/hour × months) | 1,121.1 ± 627.6 | 1,157.0 ± 537.6 |
Disease-related treatments (months during follow-up) | Â | Â |
   Nonbiologic DMARDs | 38.4 (35.1, 41.4) | 40.0 (32.6, 42.5) |
   Biologic agents | 0.0 (0.0, 39.3) | 31.6 (0.0, 41.4) |
   Corticosteroids | 40.5 (35.2, 42.3) | 33.2 (3.7, 41.7) |
Remission during follow-up (months) | 36.2 (32.4, 39.1) | 31.4 (11.3, 37.3) |
Remission during follow-up (% of follow-up time) | 90.5 (85.0, 92.9) | 84.6 (27.8, 92.6) |
Traditional cardiovascular risk factors | Â | Â |
   Hypertension at baseline, n (%) | 12 (66.7) | 17 (37.8) |
   SBP AUC during follow-up (mmHg × months) | 5,791.1 ± 634.3 | 5,416.7 ± 599.6 |
   DBP AUC during follow-up (mmHg × months) | 3,491.4 ± 306.5 | 3,333.9 ± 323.9 |
   Antihypertensive treatment (% follow-up time) | 2.3 (0, 2.4) | 0 (0, 2.3) |
   LDL ≥ 160 mg/dl and/or under statin treatment at baseline, n (%) | 8 (42.1) | 12 (26.7) |
   LDL AUC during follow-up (mg/dl × months) | 5,528.9 ± 1294.1 | 5,457.7 ± 1377.9 |
   Statin use during follow-up (% follow-up time) | 0.0 (0.0, 29.0) | 0.0 (0.0, 0.0) |
   Smoking at end of follow-up, n (%) | 7 (36.8) | 14 (31.1) |
   Total years of smoking | 30 (0.0, 40.0) | 0.0 (0.0, 29.0) |
BMI (kg/m2) | Â | Â |
   BMI at baseline | 26.1 ± 3.5 | 25.9 ± 3.7 |
   BMI at follow-up end | 26.0 ± 3.8 | 26.3 ± 4.4 |
   Positive family history of CAD, n (%) | 7 (36.8) | 8 (17.8) |
Number of CV risk factors, n (%) | Â | Â |
   0 | 0 (0) | 13 (28.9) |
   1 | 9 (47.4) | 17 (37.8) |
   2 | 7 (36.8) | 12 (26.7) |
   3 | 3 (15.8) | 3 (6.7) |
Carotid plaques at baseline, n (%) | 14 (73.7) | 16 (35.6) |